Phase I Study of Replication-Competent Adenovirus-Mediated Double-Suicide Gene Therapy in Combination with Conventional-Dose Three-Dimensional Conformal Radiation Therapy for the Treatment of Newly Diagnosed, Intermediate- to High-Risk Prostate Cancer

Cancer Research

Volumn 63, Issue 21, 2003, Pages 7497-7506

  Freytag, Svend O ^a   Stricker, Hans ^b   Pegg, Jan ^a,b   Paielli, Dell ^a   Pradhan, Deepak G ^a   Peabody, James ^a,b   DePeralta Venturina, Mariza ^a   Xia, Xueqing ^a   Brown, Steve ^a   Lu, Mei ^a   Kim, Jae Ho ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CYTOSINE DEAMINASE HERPES SIMPLEX VIRUS THYMIDINE KINASE FUSION PROTEIN; FLUCYTOSINE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; VALGANCICLOVIR; VIRUS FUSION PROTEIN;

ADULT; ADVERSE DRUG REACTION; AGED; ANEMIA; ANTIGEN DETECTION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVENTIONAL DOSE THREE DIMENSIONAL CONFORMAL RADIATION THERAPY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DOUBLE SUICIDE GENE THERAPY; DRUG SAFETY; DYSURIA; ERECTILE DYSFUNCTION; FATIGUE; FEVER; FUSION GENE; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; HEMATURIA; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; INJECTION; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MONOCYTOSIS; NEEDLE BIOPSY; NEPHROTOXICITY; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DERMATITIS; RADIATION DOSE; SUICIDE GENE THERAPY; TESTOSTERONE BLOOD LEVEL; TRANSGENE; URINARY FREQUENCY; URINARY URGENCY; URINE RETENTION; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE; VIRUS REPLICATION;

ADENOVIRUSES, HUMAN; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; CYTOSINE DEAMINASE; DNA, VIRAL; FLUCYTOSINE; GANCICLOVIR; GENE EXPRESSION; GENE THERAPY; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RECOMBINANT FUSION PROTEINS; SIMPLEXVIRUS; THYMIDINE KINASE; TRANSGENES; VIRUS REPLICATION;

EID: 10744227813     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Shipley, W., Thames, H., Sandler, H., Hanks, G., Zietman, A., Perez, C., Kuban, D., Hancock, S., and Smith, C. Radiation therapy for clinically localized prostate cancer. JAMA, 281: 1598-1604, 1999.
2. Shipley, Verhey, L., Munzenrider, J., et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int. J. Radiat. Oncol. Biol. Phys., 32: 3-12, 1995.
3. Hanks, G., Hanlon, A., Pinover, W., et al. Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int. J. Radiat. Oncol. Biol. Phys., 46: 823-832, 2000.
4. Hanks, G., Hanlon, A., Schultheiss, T., Pinover, W., Movsas, B., Epstein, B., and Hunt, M. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. Int. J. Radiat. Oncol. Biol. Phys., 41: 501-510, 1988.
5. Pollack, A., and Zagars, G. External beam radiotherapy dose response of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 39: 1011-1018, 1997.
6. Pollack, A., and Zagars, G. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int. J. Radiat. Oncol. Biol. Phys., 48: 507-512, 2000.
7. Zelefsky, M., Fuks, Z., Hunt, M., Lee, H., Lombardi, D., Ling, C., Reuter, V., Venkatraman, E., and Leibel, S. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J. Urol., 166: 876-881, 2001.
8. Zelefsky, M., Fuks, Z., Hunt, M., Yamada, Y., Marion, C., Ling, C., Amols, H., Venkatraman, E., and Leibel, S. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int. J. Radiat. Oncol. Biol. Phys., 53: 1111-1116, 2002.
9. Smit, W., Helle, P., Van Putten, W., et al. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int. J. Radiat. Oncol. Biol. Phys., 18: 23-29, 1990.
10. Ryu, J., Winter, K., Michalski, J., Purdy, J., Markoe, A., Earle, J. J., Perez, C., Roach, M., Sandler, H., Pollack, A., and Cox, J. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int. J. Radiat. Oncol. Biol. Phys., 54: 1036-1046, 2002.
11. Hankey, B., Feuer, E., Clegg, L. et al. Cancer surveillance series: Interpreting trends in prostate cancer incidence, mortality and survival rates. J. Natl. Cancer Inst. (Bethesda), 91: 1017-1024, 1999.
12. Arnling, C., Blute, M., Lemer, S., et al. Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin. Proc., 73: 401-406, 1998.
13. Jhaveri, F., Klein, E., Kupelian, P., et al. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J. Clin. Oncol., 17: 3167-3172, 1999.
14. Pollack, A., Zagars, G., Smith, L., Lee, J., von Eschenbach, A., Antolak, J., Starkschall, G., and Rosen, I. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J. Clin. Oncol., 18: 3904-3911, 2000.
15. Pollack, A., Zagars, G., Starkschall, G., Antolak, J., Lee, J., Huang, E., von Eschenbach, A., Kuban, D., and Rosen, I. Prostate biopsy radiation dose response: results of the M. D. Anderson phase III randomized trial. Int. J. Radiat. Oncol. Biol. Phys., 53: 1097-1105, 2002.
16. Pollack, A., Zagars, G., Antolak, J., Kuban, D., and Rosen, I. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int. J. Radiat. Oncol. Biol. Phys., 54: 677-685, 2002.
17. Pollack, A., Joon, D., Wu, C., Sikes, C., Hasegawa, M., Terry, N., White, R., Zagars, G., Meistrich, M. Quiescence in R3327-G rat prostate tumors after androgen ablation. Cancer Res., 57: 2493-2500, 1997.
18. Joon, D., Hasegawa, M., Sikes, C., Khoo, V., Terry, N., Zagars, G., Meistrich, M., and Pollack, A. Supra-additive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int. J. Radiat. Oncol. Biol. Phys., 38: 1071-1078, 1997.
19. Zeitman, A. L., Nakfoor, B. M., Prince, E. A., et al. The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: an in vitro and in vivo study. Cancer J. Sci. Am., 3: 31-36, 1997.
20. Lawton, C., Winter, K., Murray, K., Machtay, M., Mesic, J., Hanks, G., Coughlin, C., and Pilepich, M. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys., 49: 937-946, 2001.
21. Pilepich, M., Winter, K., John, M., Mesic, J., Sause, W., Rubin, P., Lawton, C., Machtay, M., and Grignon, D. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys., 50: 1243-1252, 2001.
22. Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J., Mirimanoff, R., Storme, G., Bernier, J., Kuten, A., Sternberg, C., Mattelaer, J., Lopez Torecilla, J., Pfeffer, J., Lino Cutajar, C., Zurlo, A., and Pierart, M. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a Phase III randomised trial. Lancet, 360: 103-106, 2002.
23. Hanks, G. E., Lu, J. D., Machtay, M., et al. RTOG Protocol 9202: a phase III trial of the use of long-term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys., 48: 112-120, 2000.
24. Pollack, A., Salem, N., Ashoori, F., Hachem, P., Sanga, M., von Eschenbach, A., and Meistrich, M. Lack of prostate cancer radiosensitization by androgen deprivation. J. Radiat. Oncol. Biol. Phys., 51: 1002-1007, 2001.
25. Freytag, S. O., Rogulski, K. R., Paielli, D. L., Gilbert, J. D., and Kim, J. H. A novel three-pronged approach to selectively kill cancer cells: concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther., 9: 1323-1333, 1998.
26. Rogulski, K. R., Wing, M., Paielli, D. L., Gilbert, J. D., Kim, J. H., and Freytag, S. O. Double suicide gene therapy augments the therapeutic efficacy of an oncolytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum. Gene Ther., 11: 67-76, 2000.
27. Freytag, S. O., Paielli, D., Wing, M., Rogulski, K., Brown, S., Kolozsvary, A., Seely, J., Barton, K., Dragovic, A., and Kim, J. H. Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model. Int. J. Radiat. Oncol. Biol. Phys., 54: 873-886, 2002.
28. Freytag, S. O., Khil, M., Stricker, H., Peabody, J., Menon, M., DePeralta-Venturina, M., Nafziger, D., Pegg, J., Paielli, D., Brown, S., Barton, K., Lu, M., Aguilar-Cordova, E., and Kim, J. H. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res., 62: 4968-4976, 2002.
29. McGinn, C., Shewach, D., and Lawrence, T. Radiosensitizing nucleosides. J. Natl. Cancer Inst. (Bethesda), 88: 1193-1203, 1996.
30. 1 restriction point into S-phase: implications for fluoropyrimidine radiosensitization. Cancer Res., 60: 92-100, 2000.
31. Moolten, F. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther., 1: 279-287, 1997.
32. Kim, J. H., Kim, S. H., Brown, S. L., and Freytag, S. O. Selective enhancement by an antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSV-tk gene. Cancer Res., 54: 6053-6056, 1994.
33. Kim, J. H., Kim, S. H., Kolozsvary, A., Brown, S. L., Kim, O. B., and Freytag, S. O. Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents. Int. J. Radiat. Oncol. Biol. Phys., 33: 861-868, 1995.
34. Khil, M., Kim, J. H., Mullen, C. A., Kim, S. H., and Freytag, S. O. Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene. Clin. Cancer Res., 2: 53-57, 1995.
35. Rogulski, K. R., Kim, J. H., Kim, S. H., and Freytag, S. O. Glioma cells transduced with an E. coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum. Gene Ther., 8: 73-85, 1997.
36. Kim, S. H., Kim, J. H., Kolozsvary, A., Brown, S. L., and Freytag, S. O. Preferential radiosensitization of 9L glioma cells transduced with HSV-TK gene by acyclovir. J. Neurooncol., 33: 189-194, 1997.
37. Rogulski, K. R., Zhang, K., Kolozsvary, A., Kim, J. H., and Freytag, S. O. Pronounced anti-tumor effects and tumor radiosensitization of double suicide gene therapy. Clin. Cancer Res., 3: 2081-2088, 1997.
38. Gable, M., Kim, J. H., Kolozsvary, A., Khil, M., and Freytag, S. O. Selective in vivo radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells transduced with the E. coli cytosine deaminase (CD) gene. Int. J. Radiat. Oncol. Biol. Phys., 41: 883-887, 1997.
39. Kim, J. H., Kolozsvary, A., Rogulski, K. R., Khil, M., and Freytag, S. O. Double suicide fusion gene: a selective radiosensitization of 9L glioma in rat brain. Cancer J. Sci. Am., 4: 364-369, 1998.
40. Xie, Y., Gilbert, J. D., Kim, J. H., and Freytag, S. O. Efficacy of adenovirus-mediated CD/5-FC and HSV-1 TK/GCV suicide gene therapies concomitant with p53 gene therapy. Clin. Cancer Res., 5: 4224-4232, 1999.
41. Kievit, E. Nyati, M., Ng, E., Stegman, L., Parsels, J., Ross, B., Rehemtulla, A., and Lawrence, T. S. Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts. Cancer Res., 60: 6649-6655, 2000.
42. Vlachaki, M., Chhikara, M., Aguilar, L., Zhu, X., Chiu, K., Woo, S., Teh, B., Thompson, T., Butler, E., and Aguilar-Cordova, E. Enhanced therapeutic effect of multiple injections of HSV-TK + GCV gene therapy in combination with ionizing radiation in a mouse mammary tumor model. Int. J. Radiat. Oncol. Biol. Phys., 51: 1008-1017, 2001.
43. Rogulski, K. R., Freytag, S. O., Zhang, K., Gilbert, J. D., Paielli, D. L., Kim, J. H., Heise, C., and Kim, D. Anti-tumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res., 60: 1193-1196, 2000.
44. Chen, Y., DeWeese, T., Dilley, J., Zhang, Y., Li, Y., Ramesh, N., Lee, J., Pennathur-Das, R., Radzyminski, J., Wypych, J., Brignetti, D., Scott, S., Stephens, J., Karpf, D., Henderson, D., and Yu, D. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res., 61: 5453-5460, 2001.
45. Teh, B. S., Aguilar-Cordova, E., Kernen, K., et al. Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer - a preliminary report. Int. J. Radiat. Oncol. Biol. Phys., 51: 605-613, 2001.
46. Michalski, J., Purdy, J., Winter, K., Roach, M., Vijayakumar, S., Sandler, H., Markoe, A., Ritter, M., Russell, K., Sailer, S., Harms, W., Perez, C., Wilder, R., Hanks, G., and Cox, J. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int. J. Radiat. Oncol. Biol. Phys., 46: 391-402, 2000.
47. Zagars, G., and Pollack, A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother. Oncol., 44: 213-221, 1997.
48. Hanlon, A., Watkins-Bruner, D., Peter, R., and Hanks, G. Quality of life study in prostate cancer patients treated with three-dimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population. Int. J. Radiat. Oncol. Biol. Phys., 49: 51-59, 2001.
49. Barton, K., Tyson, D., Stricker, H., Lew, Y., Heisey, G., Koul, S., de la Zerda, A., Yin, F-F., Yan, H., Nagaraja, T., Randall, K., Kim, J., Fenstermacher, J., Jhiang, S., Kim, J. H., Freytag, S. O., and Brown, S. L. GENIS: gene expression of sodium iodide symporter for non-invasive imaging of gene therapy vectors and quantification of gene expression in vivo. Mol. Ther., 8: 508-518, 2003.
50. Brand, K., Arnold, W., Bartels, T., Lieber, A., Kay, M., Strauss, M., and Dorken, B. Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors. Cancer Gene Ther., 4: 9-16, 1997.
51. Meek, A. G., Park, T. L., Oberman, E., and Wielopolski, L. A prospective study of prostate specific antigen levels in patients receiving radiotherapy for localized carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys., 19: 733-741, 1990.
52. Kaplan, I. D., Cox, R. S., and Bagshaw, M. A. A model of prostatic carcinoma tumor kinetics based on prostate specific antigen levels after radiation therapy. Cancer (Phila.), 68: 400-405, 1991.
53. Ritter, M. A., Messing, E. M., Shanahan, T. G., Potts, S., Chappell, R. J., and Kinsella, T. J. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J. Clin. Oncol., 10: 1208-1217, 1992.
54. Zagars, G., and Pollack, A. The fall and rise of prostate-specific antigen. Cancer (Phila.), 72: 832-842, 1993.
55. Oesterling, J., Chan, D., Epstein, J. et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostate cancer treated with radical prostatectomy. J. Urol., 139: 766-772, 1988.
56. Zagars, G. K. Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 23: 47-53, 1992.
57. Kavadi, V., Zagars, G., and Pollack, A. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications. Int. J. Radiat. Oncol. Biol. Phys., 30: 279-287, 1994.
58. Zeitman, A., Tibbs, M., Dallow, K., Smith, C., Althausen, A., Zlotecki, R., and Shipley, W. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother. Oncol., 40: 159-162, 1996.
59. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statements on radiation therapy of Prostate cancer: Guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. J. Clin. Oncol., 17: 1155-1163, 1999.
60. Critz, F., Williams, W., Holladay, C., et al. Post-treatment PSA ≤ 0. 2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques. Urology, 54: 968-971, 1999.
61. Vicini, F., Kestin, L., and Martinez, A. The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma. Cancer (Phila.), 88: 2305-2318, 2000.
62. Crook, J., Perry, G., Robertson, S., et al. Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology, 45: 624-632, 1995.
63. Crook, J., Bahadur, Y., Bociek, R., et al. Radiotherapy for localized prostate carcinoma: the correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen. Cancer (Phila.), 79: 328-336, 1997.
64. Crook, J., Bahadur, Y., Robertson, S., et al. Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma. Cancer (Phila.), 79: 81-89, 1997.
65. Crook, J., Malone, S., Perry, G., et al. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int. J. Radiat. Oncol. Biol. Phys., 48: 355-367, 2000.
66. Scardino, P., and Wheeler, T. M. Local control of prostate cancer with radiotherapy: Frequency and prognostic significance of positive results of postirradiation prostate biopsy. Natl. Cancer Inst. Monogr., 7: 95-103, 1988.
67. Kuban, D., el-Mahdi, A., and Schellhammer, P. The significance of post-irradiation prostate biopsy with long-term follow-up. Int. J. Radiat. Oncol. Biol. Phys., 24: 409-414, 1992.
68. Prestidge, B., Kaplan, I., Cox, R., et al. The clinical significance of a positive post-irradiation prostatic biopsy without metastases. Int. J. Radiat. Oncol. Biol. Phys., 24: 403-408, 1992.
69. Kestin, L., Vicini, F., and Martinez, A. Practical application of biochemical failure definitions: what to do and when to do it. Int. J. Radiat. Oncol. Biol. Phys., 53: 304-315, 2002.
70. Hanks, G., Leibel, S., Krall, J., et al. Patterns of care studies: Dose-response observations for local control of adenocarcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys., 11: 153-157, 1985.
71. Hanks, G., Martz, K., and Diamond, J. The effect of dose on local control of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 15: 1299-1305, 1988.
72. Perez, C., Walz, B., Zivnuska, F., et al. Irradiation of carcinoma of the prostate localized to the pelvis: analysis of tumor response and prognosis. Int. J. Radiat. Oncol. Biol. Phys., 6: 555-563, 1980.
73. Perez, C., Pilepich, M., Garcia, D., et al. Definitive radiation therapy in carcinoma of the prostate localized to the pelvis: Experience at the Mallinckrodt Institute of Radiology. NCI Monogr., 7: 85-94, 1988.
74. Rosser, C., Reyes, A., Vakar-Lopez, F., Levy, L., Kuban, D., Hoover, D., Lee, A., and Pisters, L. Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 56: 1-6, 2003.